Novel aggregate structure adjuvants modulate lymphocyte proliferation and Th1 and Th2 cytokine profiles in ovalbumin immunized mice

Vaccine

Volumn 18, Issue 1-2, 1999, Pages 140-152

  Rajananthanan, Palasingam ^a   Attard, George S ^b   Sheikh, Nadeem A ^a   Morrow, W John W ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Amphiphile based adjuvants; Cytokines; Th1 cells; Th2 cells; Vaccine

Indexed keywords

ADJUVANT; DENDRIMER; GLYCOLIPID; TOMATINE;

ARTICLE; CYTOKINE PRODUCTION; DRUG FORMULATION; DRUG SCREENING; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOKINES; FEMALE; IMMUNIZATION; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; OVALBUMIN; TH1 CELLS; TH2 CELLS; TOMATINE;

EID: 0033588526     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00213-3     Document Type: Article

References (51)

1. Bomford R. Will adjuvants be needed for vaccines of the future? Dev. Biol. Stand. 92:1998;13-17.
2. Sheikh N.A., Rajananthanan P., Morrow W.J.W. Immunological adjuvants: mechanisms of action and clinical application. Exp. Opin. Invest. Drugs. 5:1996;1079.
3. Kataria Y.P., Holter J.F. Immunology of sarcoidosis. Clin. Chest Med. 18:1997;719.
4. Firestein G.S., Roeder W.D., Laxer J.A., Townsend K.S., Weaver C.T., et al. A new murine CD4+ T cell subsets with an unrestricted cytokine profile. J. Immunol. 143:1989;518.
5. Paul W.E., Seder R.A. Lymphocyte responses and cytokines. Cell. 76:1994;241.
6. Mosmann T.R., Coffman R.L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol. 7:1989;145.
7. Fitch F.W., McKisic M.D., Lancki D.W., Gajewski T.F. Differential regulation of murine T lymphocyte subsets. Ann. Rev. Immunol. 11:1993;29.
8. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature. 383:1996;787.
9. Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Th1,Th2 and more. Immunol. Today. 17:1996;138.
10. Constant S.L., Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses. Ann. Rev. Immunol. 15:1997;297.
11. Yanagida M., Fukamachi H., Ohgumi K., Kuwaki T., et al. Effects of T-helper 2-type cytokines, interleukine-3 (IL-3), IL-4, IL-5 and IL-6 on the survival of cultured human mast cell. Blood. 86:1995;3705.
12. - T cells in non-MHC gene-controlling pre-disposition toward skewing into T helper type-2 immunity in BALB/c mice. J. Immunol. 158:1997;5698.
13. Street N.E., Schumacher J.H., Fong T.A.T., Bass H., Fiorentino D.F., Leverah J.A., Mosmann T.R. Heterogeneity of mouse helper T cells: evidence from bulk cultures and limiting dilution cloning for precursors of Th1 and Th2 cells. J. Immunol. 144:1990;1629.
14. Valensi J.M., Carlson J.R., Van Nest G.A. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J. Immunol. 153:1994;4029.
15. Barrios C., Brandt C., Berney M., Lambert P.H., Siegrist C.A. Partial correction of the TH2/TH1 imbalance in neonatal murine responses to vaccine antigen through selective adjuvant effects. Eur. J. Immunol. 26:1996;2666.
16. Fernando G.J., Stewart T.J., Tindle R.W., Frazer I.H. Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term. Scand. J. Immunol. 47:1998;459.
17. Audibert F., Lise L.D. Adjuvants: current status, clinical perspectives and future prospects. Immunology Today. 14:1993;281.
18. Vogel F.R. Adjuvants in perspective. Dev. Biol. Stand. 92:1998;241.
19. Gupta R.K., Rost B.E., Relyveld E., Siber G. Adjuvant properties of aluminium and calcium compounds. Powell M.F., Newmand M.K. Vaccine design. 1995;229 Plenum Press, New York.
20. Koff W.C., Glass M.J. Further direction in HIV vaccine development. AIDS Res. Human Retroviruses. 8:1992;1313.
21. Rajananthanan P., Attard G.S., Sheikh N.A., Morrow W.J.W. Evaluation of novel aggregate structures as adjuvants: composition, toxicity studies and humoral responses. Vaccine. 17:1999;715.
22. Toellner K.M., Luther S.A., Sze D.M., Choy R.K., et al. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J. Exp. Med. 187:1998;1193.
23. Constant S.L., Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses. Ann. Rev. Immunol. 15:1997;297.
24. Lenschow D.J., Walunas T.L., Bluestone J.A. CD28/B7 system of T cell costimulation. Ann. Rev. Immunol. 14:1996;233.
25. Paul W.E., Seder R.A. Lymphocyte responses and cytokines. Cell. 76:1994;241.
26. Golding B., Scott D.E. Vaccine strategies: targeting helper T cell responses. Ann. NY Acad. Sci. 754:1995;126.
27. Brewer J.M., Alexander J. Cytokines and the mechanisms of action of vaccine adjuvants. Cytokines Cell. Mol. Ther. 3:1997;233.
28. Ariail K.S., Bebo B.F., Adlard K., Robey I., et al. Novel adjuvants for induction of T-cell and antibody responses to encephalitogenic and regulatory determinants in Lewis rats. Vaccine. 16:1998;99.
29. Sjolander A., Lovgren K., Johansson M., Morein B. Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins. Scand. J. Immunol. 43:1996;164.
30. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146:1991;431.
31. Sjolander A., Land B.V., Bengtsson K.L. Iscoms containing purified quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell. Immunol. 177:1997;69.
32. Lovgren K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunisation with influenza virus immunostimulating complexes. Scand. J. Immunol. 27:1988;241.
33. Maloy K.J., Donachie A.M., Mowat A.M. Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunisation with ISCOMs. Eur. J. Immunol. 25:1995;2835.
34. Sheikh NA, Rajananthanan P, Attard GS, Morrow WJW. Generation of antigen specific CD8+ cytotoxic T cells following immunisation with stable protein formulated with novel glycoside adjuvants. Vaccine 1999;17:2974.
35. Lindblad E.B. Aluminium adjuvants. Stewart-Tull D.E.S. The theory and practical application of adjuvants. 1995;21 Wiley, New York.
36. Lindblad E.B., Elhay M.J., Silva R., Appelberg R., Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun. 65:1997;623.
37. Brewer J.M., Conacher M., Satoskar A., Bluethmann H., Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur. J. Immunol. 26:1996;2062.
38. Raychaudhuri S., Tonks M., Carbone F., et al. Induction of antigen-specific class I-restricted cytotoxic T cells by soluble protein in vivo. Proc. Natl. Acad. Sci. USA. 89:1992;8308.
39. Hariharan K., Braslawsky G., Black A., Raychadhuri S., Hanna N. The induction of cytotoxic T cells and tumour regression by soluble antigen formulation. Cancer Res. 55:1995;3486.
40. de Souza J.B., Playfair J. A novel adjuvant for use with a blood-stage malaria vaccine. Vaccine. 13:1995;1316.
41. Souberbielle B.E., Knight B.C., Morrow W.J.W., et al. Comparison of IL-2 and IL4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine. Gene Therapy. 3:1996;853.
42. Sheikh NA, van Rooijen N, Attard GS, Rajananthanan P, Morrow WJW. Mechanism of adjuvant-mediated CTC generation. II. Delivery of exogenous protein into a TAP-independent pathway. Submitted.
43. Sheikh NA, Attard GS, Nye KE, Morrow WJW. Adjuvant-mediated mechanism of adjuvant-mediated CTL generation. I. Delivery vehicles target different APC - implications for vaccine design. Submitted.
44. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1997;1623.
45. Fox B.S. Antibody responses to a cytochrome c peptide do not correlate with lymphokine production patterns from helper T-cell subsets. Immunology. 75:1992;164.
46. Kukowska-Latallo J.F., Bielinska A.U., Johnson J., Spindler R., et al. Efficient transfer of genetic material into mammalian cells using starburst polyamidoamine dendrimers. Proc. Natl. Acad. Sci. USA. 93:1996;4897.
47. Barth R.F., Adams D.M., Solway A.H., Alam F., Darby M.V. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential system for neutron capture therapy. Bioconjugat. Chem. 5:1994;58.
48. Kennedy M.K., Picha K.S., Shanebeck K.D., Anderson D.M., Grabstein K.H. Interleukin-12 regulates the proliferation of Th1 but not Th2 or Th0, clones. Eur. J. Immunol. 24:1994;2271.
49. Muraille E., Leo O. Revisiting the Th1/Th2 paradigm. Scand. J. Immunol. 47:1998;1.
50. Bomborough P., Hedgecock C.J.R., Richards W.G. The interleukin-2 and interleukin-4 receptors studied by molecular modelling. Structure. 2:1994;839.
51. Paludan S.R. Interleukin-4 and interferon-γ: the quintessence of a mutual antagonistic relationship. Scand. J. Immunol. 48:1998;459.